Approved indications (FDA): Zelboraf (vemurafenib) is approved for adults with unresectable or metastatic melanoma that harbors a BRAF V600E mutation and for patients with Erdheim‑Chester disease (ECD) with a BRAF V600 mutation, after confirmation of the mutation with an approved test.

Off‑label uses and evidence: Clinicians sometimes use vemurafenib off‑label for other BRAF V600–mutated cancers (such as some histiocytic disorders, brain tumors, and thyroid cancers) based mainly on small studies, basket trials, and case series; for many of these conditions, other BRAF or BRAF/MEK inhibitor regimens now have stronger evidence and are often preferred.

Efficacy in BRAF‑mutant metastatic melanoma: In phase III trials versus dacarbazine, Zelboraf produced objective responses in roughly half of treated patients, improved progression‑free survival to about 5–6 months, and increased one‑year overall survival compared with chemotherapy, though most patients eventually develop resistance.

Efficacy in Erdheim‑Chester disease: In the VE‑BASKET trial ECD cohort, about 55% of patients had tumor shrinkage (partial or complete responses), with most others achieving stable disease and many responses lasting beyond 2 years, making it an important option for this rare disease.

Onset of benefit and durability: Symptom relief and radiologic tumor shrinkage in melanoma often begin within the first 4–8 weeks; in ECD, imaging responses may take several months, but many responders maintain control for years if the drug is tolerated.

Comparison with other BRAF‑targeted therapies: Compared with older chemotherapy, Zelboraf offers higher response rates and better survival in BRAF‑mutant melanoma, but newer BRAF/MEK inhibitor combinations (such as dabrafenib plus trametinib or encorafenib plus binimetinib) generally provide longer disease control and are now more commonly used first‑line, with Zelboraf often considered when other options are unsuitable or have failed.

Typical dosing: For adults with unresectable or metastatic BRAF V600E‑mutant melanoma or BRAF V600‑mutant Erdheim‑Chester disease, the recommended dose is 960 mg orally twice daily (four 240‑mg tablets about 12 hours apart), continued until disease progression or unacceptable toxicity; dosing for patients under 18 years is not established.

How to take it: Swallow the tablets whole with water; do not crush, chew, or split them. Zelboraf may be taken with or without food, but it should be taken the same way each day, at consistent times. A validated test must confirm a BRAF V600 mutation before starting therapy.

Dose adjustments and special instructions: If troublesome side effects occur, the dose may be temporarily stopped and then reduced (commonly to 720 mg twice daily, and if needed to 480 mg twice daily, but not lower) or permanently discontinued for severe toxicity or persistent marked QT prolongation. Use caution and close monitoring in patients with moderate to severe liver or kidney impairment or significant cardiac risk factors, and avoid or carefully manage strong CYP3A4 inducers or other interacting drugs per prescriber guidance.

Missed doses and vomiting: If a dose is missed, it can be taken as soon as remembered as long as the next scheduled dose is more than 4 hours away; otherwise, skip the missed dose and take the next dose at the usual time, without doubling. If vomiting occurs after a dose, do not repeat that dose—resume with the next scheduled dose.

Overdose: There is no specific antidote for overdose; in case of taking more than the prescribed amount, emergency medical evaluation is needed for supportive care and monitoring of heart rhythm, electrolytes, and organ function.

Common side effects: Very frequent effects include joint pain, rash or other skin changes, photosensitivity (easy sunburn), hair loss, fatigue, dry or thickened skin, nausea, diarrhea, and benign skin growths such as papillomas or warts. Many people experience at least one skin‑related problem, often beginning in the first weeks of therapy and ranging from mild to bothersome but manageable with dose adjustments and supportive care.

Serious or rare adverse effects: Zelboraf can cause new skin cancers (especially cutaneous squamous cell carcinoma and, less often, new primary melanoma) that usually require surgical removal; serious allergic reactions, severe skin reactions such as Stevens–Johnson syndrome or toxic epidermal necrolysis, and a life‑threatening rash with systemic symptoms (DRESS) have been reported and require immediate discontinuation. It can also prolong the QT interval and trigger dangerous heart rhythm problems, cause liver injury, kidney injury, eye inflammation (uveitis or other ocular events), and very rarely promote non‑skin cancers driven by RAS activation.

Warnings and precautions: Zelboraf must not be used in tumors without a BRAF V600 mutation because it may accelerate growth of BRAF wild‑type cancers. It should be used with great caution in patients with a history of serious arrhythmias, uncontrolled electrolyte abnormalities, severe liver or kidney impairment, or prior severe skin reactions. It can harm an unborn baby, so effective contraception is recommended during treatment and for at least 2 weeks after the last dose, and breastfeeding is not advised during treatment or for 2 weeks afterward. Safety and efficacy are not established in children and adolescents, and older adults may be more prone to skin and systemic side effects.

Comparative safety profile: Like other BRAF inhibitors, Zelboraf has a distinctive profile dominated by skin toxicities, photosensitivity, and risk of secondary skin cancers; combining a BRAF inhibitor with a MEK inhibitor in other regimens tends to reduce some proliferative skin events but can introduce other toxicities (for example, more fever with dabrafenib plus trametinib).

Monitoring and safety follow‑up: Patients typically need baseline and periodic ECGs and electrolyte checks for QT prolongation; regular liver and kidney function tests; dermatologic exams before treatment, every couple of months during therapy, and for several months after stopping; and prompt eye evaluation if vision changes, eye pain, or redness occur.

Reporting side effects and safety updates: Side effects should be reported to the treating clinician as soon as possible, and in the United States serious suspected reactions can also be reported directly to the FDA through the MedWatch program (online or by phone), where ongoing safety communications and label updates are posted.

Prescription drug interactions: Zelboraf is metabolized by and can affect liver enzymes (especially CYP3A4 and CYP1A2) and drug transporters (such as P‑glycoprotein). Strong CYP3A4 inhibitors (for example, some azole antifungals, macrolide antibiotics, and HIV protease inhibitors) can raise vemurafenib levels and increase toxicity, while strong CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin, and St John’s wort) may lower levels and reduce efficacy; these combinations are generally avoided or require careful dose adjustment and monitoring. Vemurafenib can increase exposure to drugs that rely on CYP1A2 or P‑gp for clearance (such as theophylline or digoxin), so closer monitoring or dose changes of those medicines may be necessary.

Other medicines and QT‑prolonging agents: Because Zelboraf can prolong the QT interval, combining it with other drugs that also prolong QT (such as certain antiarrhythmics, fluoroquinolone antibiotics, some antipsychotics, or methadone) increases the risk of serious arrhythmias and is avoided whenever possible, with ECG and electrolyte monitoring if such combinations cannot be avoided. Concomitant use with ipilimumab has been associated with higher rates of liver toxicity and is generally not recommended.

OTC medicines, supplements, and foods: Non‑prescription pain relievers, cold remedies, and herbal products can interact indirectly by affecting the heart, liver, or kidney or by altering CYP enzymes; the prescriber or pharmacist should review all over‑the‑counter and supplement use. Grapefruit and Seville orange products can inhibit CYP3A4 and may increase vemurafenib levels, so they are typically avoided during treatment. Alcohol should be limited because of potential additive liver strain, dehydration, and heart‑rhythm effects.

Precautions and conditions where use may be unsafe: Zelboraf should not be used in cancers that are BRAF wild‑type, given the risk of paradoxical tumor stimulation. Particular caution and intensive monitoring are needed in patients with a history of serious skin reactions, uncontrolled electrolyte abnormalities, pre‑existing long‑QT syndrome or significant heart disease, moderate to severe hepatic or renal impairment, or prior radiation therapy (because of a risk of radiation sensitization or radiation‑recall reactions).

Monitoring during therapy: Before starting treatment and periodically thereafter, patients usually need: confirmation of BRAF V600 mutation; ECGs and serum electrolytes (especially potassium, magnesium, and calcium) to track QT interval; liver and kidney function tests; dermatologic examinations for new or changing skin lesions; and, when indicated, eye examinations and blood pressure monitoring. Results of these tests may lead to dose modification, temporary interruption, or discontinuation to maintain safety.

Q: How long does it take for Zelboraf to start working?
A: Many patients with BRAF‑mutant metastatic melanoma begin to see tumor shrinkage or symptom improvement within the first 1–2 months, while in Erdheim‑Chester disease radiologic responses may take several months, although some symptom relief can occur sooner.

Q: Do I have to avoid the sun completely while taking Zelboraf?
A: Zelboraf can make your skin much more sensitive to sunlight, so you should minimize direct sun exposure, wear protective clothing and a wide‑brimmed hat, and use broad‑spectrum sunscreen and lip balm (SPF 30 or higher) whenever you are outdoors.

Q: Can I take Zelboraf with food or other daily medicines?
A: You may take Zelboraf with or without food but should take it the same way each day at regular times; many other medicines can interact with it, so all prescription drugs, over‑the‑counter products, and supplements should be reviewed and managed by your oncology team.

Q: What happens if I miss a dose of Zelboraf?
A: If you remember and your next dose is more than 4 hours away, take the missed dose right away; if it is less than 4 hours until your next dose, skip the missed dose and just take the next dose at the usual time without doubling.

Q: Is hair loss from Zelboraf permanent?
A: Hair thinning or loss is common during treatment but is usually reversible, and hair often starts to regrow once the drug is reduced or stopped, although the color or texture may change.

Q: Can I become pregnant or breastfeed while on Zelboraf?
A: Zelboraf can harm an unborn baby and is not recommended during pregnancy, so effective contraception is advised during treatment and for at least 2 weeks after the last dose, and breastfeeding should be avoided during this period as well.

Q: Will I need regular tests while taking Zelboraf?
A: Yes, you will typically have periodic blood tests, heart tracings (ECGs), skin checks, and sometimes eye exams to monitor for side effects and guide any needed dose adjustments.

Storage: Keep Zelboraf tablets at room temperature (about 68–77°F or 20–25°C), in the original tightly closed container, protected from moisture and excessive heat; store out of reach of children and pets.

Handling: Leave tablets in the bottle until use, do not crush or chew them, and wash hands after handling if you are helping someone else with their medicine.

Disposal: Do not throw unused tablets in household trash or flush them; instead, use a pharmacy or community drug take‑back program, or follow pharmacist instructions for safe disposal if a take‑back option is not available.